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Parvovirus B19 is a common human pathogen maintained by horizontal transmission between acutely
infected individuals. However, B19 virus can also be detected in tissues throughout the life of the host, although
little is understood about the nature of such persistence. In the current study, we created large VP1/2 sequence
data sets of plasma- and tissue (autopsy)-derived variants of B19 virus with known sample dates to compare
the rates of sequence change in exogenous virus populations with those in persistently infected individuals. By
using linear regression and likelihood-based methods (such as the BEAST program), we found that plasma-
derived B19 virus showed a substitution rate of 4 104 and an unconstrained (synonymous)-substitution rate
of 18  104 per site per year, several times higher than previously estimated and within the range of values
for mammalian RNA viruses. The underlying high mutation frequency implied by these substitution rates may
enable rapid adaptive changes that are more commonly ascribed to RNA virus populations. These revised
estimates predict that the last common ancestor for currently circulating genotype 1 variants of B19 virus
existed around 1956 to 1959, fitting well with previous analyses of the B19 virus “bioportfolio” that support a
complete cessation of genotype 2 infections and their replacement by genotype 1 infections in the 1960s. In
contrast, the evolution of B19 virus amplified from tissue samples was best modeled by using estimated dates
of primary infection rather than sample dates, consistent with slow or absent sequence change during
persistence. Determining what epidemiological or biological factors led to such a complete and geographically
extensive population replacement over this short period is central to further understanding the nature of
parvovirus evolution.
Parvovirus B19 is the best-characterized member of the fam-
ily Parvoviridae, known to cause pathogenic infections in hu-
mans (14). Parvoviruses are classified into genera or groups
with differences in host range, pathology, and tissue/cellular
tropisms (14). Human parvovirus B19 is a member of the
Erythrovirus genus that specifically targets erythroid progenitor
cells through the globoside P antigen (2). Infections are asso-
ciated with anemia and sometimes with aplastic crises.
B19 virus has respiratory, vertical (where infection may lead
to intrauterine anemia or fetal death [hydrops fetalis] [4]), and
parenteral (often through the contamination of plasma-de-
rived blood products [3]) routes of transmission. Primary in-
fections are characterized by an intense viremia of short dura-
tion, a rapid resolution following seroconversion for antibody
to B19 virus, and lifelong immunity from reinfection (23). In
Western countries, the frequency of B19 virus exposure rises
steeply with age in individuals between the ages of 1 year
and the late-teenage years to approximately 60 to 70% (13,
28, 33, 44).
Little is known about the origin, past epidemiology, or evo-
lution of B19 virus. However, the lifelong persistence of viral
DNA in tissues (11, 15, 19, 22, 30, 41) may reveal what variants
circulated in previous decades of life when primary infections
occurred (30). There are three genotypes of B19 virus, differing
in nucleotide sequence by approximately 13 to 14% (6, 16, 29,
37); genotypes 1 and 2 are found in Europe, the United States,
and other Western countries, while genotype 3 is restricted to
sub-Saharan Africa and South America (6, 31, 34). Sequences
of both genotype 1 and 2 were found in tissues of persistently
infected individuals, although genotype 2 detection was strictly
limited to those born before 1973, indicating that the circula-
tion of this genotype ceased in Finland and Germany after this
date (30). A similar restriction of genotype 2 to those born
before 1963 was found in study subjects from Scotland (27),
indicating some commonality in the transmission networks and
dynamics of B19 over large areas of Europe.
The relatively dynamic picture of B19 virus populations sug-
gested by these findings has reawakened interest in the evolu-
tion and molecular epidemiology of B19 virus. To estimate the
times of origin of genotype 1 variants that replaced genotype 2
in Europe, we created and analyzed a large data set of geno-
type 1 VP1/VP2 sequences of plasma-derived (n  33) viruses.
We additionally studied tissue-derived variants of B19 virus to
compare the evolution of horizontally transmitted, exogenous
virus populations with that of virus populations occurring dur-
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ing persistent infection in vivo. The rate of the sequence
change of B19 virus was several times higher than previously
determined (31, 38), suggesting a much shorter time frame for
the emergence of genotype 1, which fits better with the “bio-
portfolio” evidence for its replacement of genotype 2 in West-
ern countries.
MATERIALS AND METHODS
Study samples. Samples of plasma from study subjects with acute B19 infec-
tion and plasma pools or manufactured blood products were obtained from the
United Kingdom, Finland, or Germany (see Table S1 in the supplemental ma-
terial). Autopsy samples of bone marrow or lymphoid tissue and 15 biopsies of
tonsil or skin collected in Finland and the United Kingdom were additionally
studied.
Amplification of B19 virus sequences. DNA was extracted from tissue and
plasma/blood product samples by standard methods (27, 30) and screened for
B19 virus DNA sequences by B19 virus-nested PCR (26). The whole of the open
reading frame 2 (ORF2) gene was amplified from positive samples by using three
sets of nested primers (see Table S2 in the supplemental material). Amplicons
were sequenced using the BigDye Terminator kit (Applied Biosystems), and
sequences were assembled and aligned in Simmonic Sequence Editor v1.5 (40).
The sequence data set was supplemented with published sequences with anno-
tated sample dates and sources (i.e., plasma or tissue) or provided by the inves-
tigators (see Table S3 in the supplemental material).
Screening for recombination and positive selection. All sequences were
screened for recombination through the detection of phylogeny violations be-
tween trees constructed from sequential 501-base fragments, increasing by 252-
base increments through the ORF2 region by using a TreeOrder scan in a
Simmonic package. The only violations detected at a bootstrap value of 65%
involved the previously described recombinant sequence AN66 (38), which was
excluded from further analysis. No evidence for positively selected amino acid
residues among the remaining data set of 121 ORF2 sequences was obtained by
using CodeML (45) or by using the HyPhy package (all P values were 0.01
[32]).
Phylogenetic analysis and rate calculation. Phylogenetic trees of B19 virus
ORF2 sequences were constructed by neighbor-joining of Jukes-Cantor analysis
(J-C)-corrected pairwise distances. Regression analysis was performed by using
maximum composite likelihood (MCL) distances (calculated by MEGA4 [43]
with a gamma distribution value of 0.179) between each sequence and the
earliest dated sequence available, PVBPRO. The separate regression analysis of
synonymous sites was performed by using J-C-corrected distances.
A Markov chain Monte Carlo (MCMC) method implemented in BEAST
package version 1.4 (9) was used to independently estimate the rate of the
sequence change of B19 virus (10). Dated sequence sets were run with chain
lengths of 10 million under the SRD06 model of substitution (39) and the
assumption of a constant population size. Separate runs using a strict molecular
clock and a relaxed (uncorrelated lognormal) clock were carried out. All other
parameters were optimized during the burn-in period. The output from BEAST
was analyzed by using the program TRACER (http://beast.bio.ed.ac.uk/Tracer).
Nucleotide sequence accession numbers. B19 virus sequences were assigned
the accession numbers EU478527 to EU478589 (see Table S1 in the supplemen-
tal material).
RESULTS
Sequence variability of B19 virus. Sequence diversity within
and between genotypes of B19 virus occurs primarily at syn-
onymous sites. We examined further constraints on B19 virus
sequence changes other than protein coding in ORF1 and
ORF2 by measuring the synonymous-site variability (SSV)
within (Fig. 1A) and between (Fig. 1B) genotypes. A region of
suppressed SSV was observed in the overlap of ORF1 and the
7-kDa protein translated from a different reading frame (po-
sitions 1904 to 2122 [25]) and in the overlap with the 11-kDa
protein gene with ORF2 (positions 4704 to 4988 [42, 46]). A
third conserved coding sequence in all three genotypes, re-
ferred to previously as the “X” ORF (14), was associated with
profound suppression of SSV between positions 2650 and
3200. The alternative reading frame was under a greater se-
quence constraint than ORF2 (Table 1), with lower nonsyn-
onymous-site variability in the “X” ORF than in ORF2 and a
lower ratio of nonsynonymous evolutionary changes (dN) to
synonymous changes (dS) (0.3). All regions of ORF2 with
FIG. 1. Variability of ORF1 and ORF2 coding sequences mea-
sured as mean pairwise synonymous distances between sequences of
the same genotype (A) and different genotypes (B) (note the different
y axis scales between panels A and B). Analysis was carried out using
201-base fragments increasing by 24-base increments across each cod-
ing region. ARF, alternate reading frame.
TABLE 1. Comparison of sequence diversity levels in ORF2 and
an alternate reading frame
Frame Position Type ofcomparison dS
a dNa dN/dS
ORF2 2714–2729 Intragenotypeb 0.0139 0.0096 1.21
Intergenotype 0.0733 0.0363 0.59
“X” ORF 2712–2930 Intragenotype 0.0261 0.0053 0.28
Intergenotype 0.1011 0.0259 0.28
a J-C-corrected mean pairwise distances.
b Weighted pairwise comparison of sequences of the same genotype.
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overlapping coding sequences were excluded from subsequent
evolutionary analysis.
Time-related sequence change of B19 virus ORF sequences.
Phylogenetic analysis of B19 virus sequences from positions
3242 to 4612 in ORF2 amplified from 33 plasma samples or
from archived plasma pools/blood products and 17 published
plasma-derived sequences of known collection dates was car-
ried out. This showed evidence for the time-related sequence
drift of B19 virus (Fig. 2A), with increasing divergence from
the root of the tree with later sampling dates. Regression
analysis of nucleotide distances between each sequence and
PVBPRO with consideration of the sample collection date
(Fig. 3) revealed the rate of sequence change of each sequence
data set to be around 4.4  104 substitution per site per year
(Table 2). Sequence changes at synonymous sites showed the
same time-related correlation (R2  0.51) and a much higher
substitution rate (18  104 substitution per site per year). No
association between sequence divergence at nonsynonymous
sites and time was detected in either data set.
To investigate whether B19 virus genotypes evolved in a
FIG. 2. Phylogenetic analysis of plasma-derived (A) and autopsy/biopsy sample-derived (B) B19 virus sequences from this study (circles) and
published sources (diamonds). Trees were constructed from pairwise J-C-corrected nucleotide distances by neighbor-joining. Symbols were colored
based on the calendar year of collection (see the key). The robustness of groupings was calculated by bootstrap resampling of 1,000 replicates of
the data; values of 70% are shown.
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comparable manner during persistence, the same analysis was
performed on sequences recovered from tissue samples (Fig.
2). The observable lack of temporal structure in the tree (Fig.
2B) was confirmed by the lack of correlation between the
sample date and divergence as determined by regression anal-
ysis (Fig. 3B; Table 2) (R2, 0.001; P, 0.05).
The same data sets were analyzed by the Bayesian MCMC
method (10). For plasma-derived sequences, applying strict
and relaxed molecular clocks predicted almost identical log
likelihoods and nucleotide substitution rates (3.64  104 and
3.72  104 substitution per site per year) (Table 2). The
relaxed clock assumption provided a mean branch substitution
rate of 4.11  104 substitution per site per year (data not
shown). Allowing a variable rate fitted the data significantly
better than allowing a uniform rate (a log10 Bayes factor of
5.428), although likelihoods and substitution rates were similar
(Table 2), indicating that the uniform-rate assumption pro-
vides an adequate model for the evolution of B19 virus. The
MCMC estimates of the substitution rate were, furthermore,
close (within 5 to 15%) to those calculated by regression anal-
ysis (4.4  104 substitution per site per year) (Table 2), lying
within the high-probability distribution (HPD) of the MCMC
values. Predicted dates for the most recent common ancestor
(MRCA) of the sequence analyzed in the plasma-derived data
set were from 1956 to 1959 (the HPD range was 1941/1945 to
1968/1969) (Fig. 2).
The substitution rates calculated for autopsy-derived vari-
ants of B19 virus by the MCMC method were 10-fold lower
than those calculated for plasma-derived viruses (Table 2). The
lower HPD interval was close to zero, consistent with an ex-
tremely low consistent rate of or undetectable sequence
change among these sequences. These data are consistent with
the lack of association between divergence and sample by re-
gression analysis (Fig. 2B).
Rate of sequence change of B19 virus during persistence.
The lack of correlation between divergence and sample year
observed for tissue-derived B19 virus variants may be ac-
counted for by restricted or absent virus replication during
persistence. The immediate problem with investigating this
hypothesis is the lack of information about the time of primary
infection in the study subjects from whom tissue samples were
obtained. However, as a group, their most likely expected
times of infection may be inferred from standard incidence and
seroprevalence information on B19 virus from the United
Kingdom and Finland. Both countries showed a period of peak
incidence between 8 and 9 years of age, at which time, overall
seroprevalence was 35% (i.e., approximately half that of the
adult population) (28).
From the subset of study subjects whose ages at the time of
sampling were recorded (see Table S1 in the supplemental
material), we compared two models of sequence change.
Model A assigns a mean time of infection of 9 years of age and
assumes no sequence change during the time that the virus
persisted. Model B assumes a sequence change after infection
at the same rate as that of the exogenous, horizontally trans-
mitted virus. Model A provides a convincing correlation be-
tween the time of infection and the substitution rate at all and
at silent sites (Table 3) (R2  0.32 to 0.33; P  0.01; substitu-
tion rates, 3.2  104 and 12.9  104 per site per year).
Lower correlation coefficients likely arose from a greater scat-
ter of the data associated with the introduction of a further
variable (age of infection) and the lower number of subjects
analyzed. The average of the measured substitution rates of
(3.7  2.0)  104 and (18.3  8.5)  104 substitution per
site per year at all and at synonymous sites, respectively, were
remarkably similar (although with higher standard errors) to
estimates based on regression analysis for plasma virus (Table
2). No such association is evident in model B (concordant with
the analysis of the larger data set) (Table 2).
FIG. 3. Relationship between sample date and divergence (MCL-
corrected pairwise distances) between the sequence of the reference
strain of B19 virus, PVBPRO (collected in 1973), and plasma-derived
(A) and autopsy/biopsy-derived (B) sequences. Previously published
(open circles) and newly obtained (filled circles) sequences are shown.
Each graph includes a line of best fit, calculated according to the linear
region.
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DISCUSSION
Substitution rate of B19 virus. Both the MCMC and regres-
sion analyses found consistently high, concordant substitution
rates of around 4  104 substitution per site per year for B19
virus in ORF2 (Table 2), approximately fourfold higher than
those calculated for this region by the MCMC method for a set
of 38 genotype 1 sequences (38). The rate is additionally sub-
stantially higher than that calculated for genotype 3 sequences
(31) and for a short region of VP1 of South American genotype
1 variants (1).
There are two likely reasons for the observed discrepancies
in rates between studies. Previous analyses of ORF2 included
regions of suppressed variability in VP1 containing overlapping
gene sequences which effectively drove SSV in the VP1 coding
frame down to close to zero. The inclusion of these relatively
invariant regions in the analysis in previous analyses of the
gene coding VP1/2 (31, 38) substantially reduced the overall
substitution rates calculated.
The second reason for lower estimates in previous studies is
the result of the inclusion of sequences derived from biopsy or
autopsy tissue samples (e.g., 11 of 38 VP1/2 sequences ana-
lyzed by Shackelton and Holmes [38]). However, we have
shown that sequence change in B19 virus variants during the
time of virus persistence is not modeled adequately by assum-
ing that they have the same substitution rate as horizontally
transmitted viruses (Table 3, model B). To demonstrate the
effect of their inclusion, we analyzed a combined data set of
plasma- and tissue (autopsy)-derived B19 virus variants by the
MCMC method and obtained a composite substitution rate for
B19 virus of 1.66  104 (HPD, 1.17  104 to 2.19  104)
substitution per site per year, three times lower than the rate
based on plasma-derived viruses. This figure would be even
lower if regions of suppressed variability in VP1 had been
included in the analyzed sequences.
Comparison with substitution rates of other viruses. The
sequence change in VP1/2 and elsewhere in the B19 virus
genome is constrained by extreme conservatism in its amino
acid sequence of encoded viral proteins (14). Almost all se-
quence change (even between the more divergent genotypes of
B19 virus) occurs at synonymous sites, with extremely low
dN/dS ratios for both major genes (31, 38). A fairer compari-
son of the underlying frequency and fixation of mutations in
the B19 virus population with those of other viruses (whose
protein sequence may not be under such constraint or may
indeed be subject to positive selection) may be achieved by
comparing synonymous-substitution rates. In the current study,
regression analysis was allowed to calculate an unconstrained-
substitution rate for B19 virus of at least 1.8  103 synony-
mous substitution per site per year (Table 2). This rate lies
within the range (of substitutions per site per year) reported
for flaviviruses (0.4 103 to 4.9 103 [restricted to nonzero
rates]), paramyxoviruses (0.7  103 to 4.8  103), and
orthomyxoviruses (0.4  103 to 4.2  103) but was higher
than ranges reported for togaviruses and reoviruses (0.1  103
to 0.78  103 and 0.6  103 to 1.4  103, respectively) and
lower only than those reported for picornaviruses (2.5  103
to 12  103).
The factors that contribute to the rapid sequence drift of


























Plasma This study All 33 0.497 5  106 4.23  0.77
Published
sequences
All 17 0.442 0.004 4.40  1.28
Combined All 50 0.547 109 4.42  0.58 51 Strict 3,645 3.64 (2.54–4.57) 1959 (1945–1968)
Relaxed 3,629 3.72 (2.66–4.84) 1956 (1941–1969)
Combined Synonymous 50 0.510 6  109 17.86  2.54
Combined Nonsynonymous 50 0.047 0.131 NAc
Autopsy This study All 29 0.039 0.300 NA
tissue Published All 17 0.300 0.053 NA
Combined All 46 0.000 0.895 NA 46 Strict 3,285 0.44 (0.014–0.97) NA
Relaxed 3,263 0.46 (0.001–1.06) NA
Combined Synonymous 46 0.002 0.781 NA
Combined Nonsynonymous 46 0.014 0.431 NA
a Significant values (P  0.05) are bold.
b Mean rate  standard error.
c NA, not applicable. With substitution rates, there was no evidence for time-related sequence change.
d Mean value (HPD interval).






All sites Synonymous sites
R2 Pd Rate(104) R
2 Pd Rate(104)
A 19 0.330 0.01 3.2  1.1 0.318 0.01 12.9  4.6
B 19 0.000 0.95 NAc 0.038 0.80 NA
a For model A, infection was considered to have occurred at the age of 9 years,
with no subsequent sequence change; for model B, the rates of sequence change
of exogenous and persistent B19 viruses were considered to be equal.
b For model A, Excludes study subjects with estimated dates of infection
before 1973 were excluded. For study subjects aged 9 years or less, infections
assumed to have occurred halfway between birth and the sampling time. For
model B, the analysis was restricted to the same subset as that used for model A.
c NA, not applicable. There was no evidence for a time-related sequence
change.
d Boldface values are significantly different.
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B19 virus and potentially to the drift of other parvoviruses
maintained by long, horizontal transmission chains are un-
known. B19 virus, in common with other small viruses, is rep-
licated by host cell DNA polymerase, and the enzyme’s intrin-
sic proofreading activity might be expected to reduce the
frequency of nucleotide misincorporations to that of host DNA
copying. In primates, this mutation frequency leads to a syn-
onymous-substitution rate of approximately 2  109 substi-
tution per site per year (5), around a million times slower than
that calculated for B19 virus. The difference in substitution
rates cannot be entirely attributed to differences in the number
of replicative cycles between B19 virus and its human host.
Human DNA in the germ line is copied approximately 30
(females) and 200 (males) times per generation, an average of
around 5 times per year. B19 virus cannot possibly undergo 5
million sequential genome replications in a year. With a min-
imum replication cycle in cells of at least 24 h, during which
time at most 10 to 20 sequentially templated copyings of the
viral genome during the synthesis of concatamerized replica-
tion intermediates are likely to occur (8), there would be a
maximum of 7,000 sequential genome transcriptions per year.
This total is nearly 1,000 times fewer than that expected if B19
virus and human DNA replication occurred with the same
underlying mutation frequency.
It is possible that the unidirectional synthesis of DNA during
the rolling hairpin replication of parvovirus DNA, resolution,
and synthesis of single-stranded genomic DNA sequences for
packaging (8) may be associated with higher error frequencies
than the bidirectional synthesis of host genomic DNA. Inter-
estingly, substitution rates in RNA viruses are correlated with
genome size, with lower rates occurring in viruses with larger
genomes (18). This provides evidence that viruses, in common
with larger organisms, have the ability to modulate mutation
rates to provide the correct balance between replicative fitness
and adaptability. One might speculate that some small DNA
viruses, such as B19 virus, may have a similar ability to modify
the mutation rates of the host cell, perhaps because its trans-
mission and epidemiology, and thus its evolutionary con-
straints and pressures, might closely resemble those of respi-
ratory viruses with RNA genomes. How this might be achieved
is not known.
Recent spread of parvovirus B19 virus. Revised estimates
for the substitution rates of B19 virus predict a relatively recent
date for the MRCA of genotype 1 (Europe, the United States,
Japan, Korea, and Brazil). An MRCA occurring in the late
1950s is consistent with the epidemiology of genotype 1 and
genotype 2. The large-scale surveillance of B19 virus genotypes
in Europe showed that genotype 1 infections are almost invari-
ably detected in contemporary samples, with extremely few if
any genotype 2 (or 3) infections (6, 7, 21). This contrasts with
the frequent detection of genotype 2 variants in tissue samples
or persistently infected (immunosuppressed) individuals (16,
24, 27, 30, 36). The hypothesis that these variants originate
from primary infections when genotype 2 was the predominant
circulating virus (30) is supported by the unusual age restric-
tions of type 2-infected subjects (those born before 1973 and
1963 [27, 30]). These observations are fully consistent with the
predicted MRCA of genotype 1 in the late 1950s, which then
almost entirely replaced genotype 2 by the early 1970s over
large parts of the world. The epidemiological factors and the
possible role of biological differences between genotypes, such
as greater infectivity or transmissibility, that may have contrib-
uted to its dramatic spread and replacement of other geno-
types are entirely unknown (12).
Nature of B19 virus sequence change during persistence.
The observation that the sequence divergence of tissue-asso-
ciated variants showed no correlation with sample collection
dates demonstrates directly that the evolution of B19 virus
during its persistence differs from that of horizontally trans-
mitted viruses. However, paired samples from acute infection
and after a period of persistence were not available to directly
investigate the sequence change, and this study had to rely on
estimates of times of infection based on those determined by
previous seroepidemiological studies (13, 28, 33, 44). However,
the crude model used in the current study (primary infections
at the age of 9 and no subsequent sequence change during
persistence) actually fitted the evolutionary data closely and
restored the correlation between sequence divergence and the
estimated year of primary infection (Table 3).
Models A and B compared in this study are extremes, and
the observed better fit of model A to the data clearly does not
rule out other scenarios, such as the persistence of the virus
with a much lower rate of sequence change arising from re-
stricted virus replication or ongoing rapid sequence change in
a small subset of individuals and an absence in the majority.
Observations for maintained strong cytotoxic-T-cell reactivity
in B19 virus-seropositive individuals (17) and low-level fluctu-
ating viremia in 0.3 to 0.8% of healthy blood donors (20, 35) do
indeed imply various degrees of ongoing replication in vivo. It
remains uncertain whether individuals with reactivated virus
may be infectious; it is therefore possible that the infrequent
cases of genotype 2 infections recorded in Europe (7, 21, 24)
may have arisen by the transmission of reactivated virus from
persistently infected individuals rather than by the continued
low-level circulation of this genotype in the community.
Understanding the nature of the persistence of B19 virus is
therefore important for future investigations of its molecular
epidemiology and evolution and of the factors underlying the
large-scale population replacements that we have witnessed in
the past few decades.
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